Skip to content

Collegium Pharmaceutical

US · COLL #3535 by market cap Listed 2015
24.72 -0.49 -1.94%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 24 in the most recent period (2026/Q3).
  • Total institutional ownership rose 6.6 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
132.02% +6.55pp
Institutions
320 -24
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund99.43%
Hedge Fund24.15%
Public Company5.43%
Individual/Insider1.17%
Government Pension Fund1.07%
Private Company0.84%
Family Office/Trust0.41%
Insurance Company0.38%
Bank/Investment Bank0.16%

Top holders as of 2026-09-30

BlackRock 17.53% · 5.45M sh
Millennium Management LLC 7.73% · 2.40M sh
Janus Henderson Group plc 6.91% · 2.15M sh
State Street Global Advisors 5.70% · 1.77M sh
Fuller & Thaler Asset Management, Inc. 5.25% · 1.63M sh
Principal Global Investors, LLC 4.87% · 1.51M sh
Renaissance Technologies Corp. 4.53% · 1.41M sh
MFS Investment Management 4.52% · 1.41M sh
Vanguard Capital Management, LLC 4.43% · 1.38M sh
Eventide Asset Management, LLC 4.38% · 1.36M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 19 buys · 30 sells

NameRoleStake
Colleen Tupper Chief Financial Officer 0.20%
John Fallon Former Independent Director 0.18%
Gino Santini Independent Chairperson 0.14%
Michael Heffernan Former Co-Founder & Chairman 0.14%
John Freund Independent Director 0.14%
Vikram Karnani Chief Executive Officer 0.13%
Thomas Smith Chief Medical Officer 0.12%
Rita Balice-Gordon Independent Director 0.07%
Gwen A. Melincoff Former Independent Director 0.04%
Nancy Lurker Independent Director 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-29 Scott Dreyer Former Executive Vice President Intent to Sell (Form 144) -27,419 $22.00
2026-07-16 John Fallon Former Independent Director Intent to Sell (Form 144) -13,920 $35.73
2026-07-14 John Fallon Former Independent Director Intent to Sell (Form 144) -8,095 $36.32
2026-06-07 Gino Santini Independent Chairperson Derivative Exercise and Retained +8,700 $16.49
2026-05-17 John Freund Independent Director Open Market Disposition -20 $34.05
2026-05-14 John Freund Independent Director Derivative Exercise and Sale -4,127 $16.49–34.54
2026-05-14 John Freund Independent Director Derivative Exercise and Retained +4,573 $16.49
2026-05-13 John Freund Independent Director Other Acquisition +8,741 --
2026-05-13 Nancy Lurker Independent Director Other Acquisition +8,741 --
2026-05-13 Garen Bohlin Independent Director Other Acquisition +8,741 --
2026-05-13 Gino Santini Independent Chairperson Other Acquisition +8,741 --
2026-05-13 Carlos Paya Independent Director Other Acquisition +8,741 --
2026-05-13 Rita Balice-Gordon Independent Director Other Acquisition +8,741 --
2026-05-13 Michael Donovan Independent Director Other Acquisition +17,482 --
2026-05-12 Nancy Lurker Independent Director Open Market Disposition -4,500 $35.97
2026-05-10 Garen Bohlin Independent Director Derivative Exercise and Sale -8,700 $16.49–37.18
2026-03-17 David Dieter General Counsel Automatic Disposition -13,976 $34.92
2026-03-16 David Dieter General Counsel Sale to Issuer -8,840 $35.72
2026-03-08 David Dieter General Counsel Automatic Disposition -6,224 $36.65
2026-03-02 Scott Dreyer Former Executive Vice President Automatic Disposition -49,976 $40.36–40.99

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Collegium Pharmaceutical discussion 0 comments

Add a comment